SciSparc Ltd.SPRC
Price (close)
$5.39
Market cap
$124.4M
P/E
—
Revenue (FY)
$1.3M
Net income
-$6.3M
Dividend yield
—
1-year total return
-90.2%
Net margin
-481.2%
Revenue growth
-54.6%
Debt / equity
—
What SciSparc Ltd. does.
pharmaceutical developments. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
With this focus, through our majority owned subsidiary NeuroThera, we are currently engaged in the following development programs based
on THC and/or non-psychoactive CBD: SCI-110 for the treatment of TS and for the treatment of Alzheimer’s disease and agitation;
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.3M | $2.9M | $1.3M |
| Net income | $4.7M | $3.5M | -$5.8M | -$2.6M | -$5.1M | -$6.3M |
| Free cash flow | -$4.7M | — | -$5.1M | -$7.9M | — | — |
More on SPRC.
- SciSparc Ltd. summary
- SciSparc Ltd. financial statements
- SciSparc Ltd. key metrics
- SciSparc Ltd. health scores and style box
- SciSparc Ltd. earnings
- SciSparc Ltd. dividends
- SciSparc Ltd. valuation
- SciSparc Ltd. ownership and insiders
- SciSparc Ltd. peers
Figures from SciSparc Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.